-
Jung-Mao Hsu,
Chun-Te Chen,
Chao-Kai Chou,
Hsu-Ping Kuo,
Long-Yuan Li, Chun-Yi Lin,
Hong-Jen Lee,
Ying-Nai Wang,
Mo Liu,
Hsin-Wei Liao,
Bin Shi,
Chien-Chen Lai,
Mark T Bedford,
Chang-Hai Tsai,
Mien-Chie Hung
[show abstract]
[hide abstract]
ABSTRACT: Epidermal growth factor receptor (EGFR) can undergo post-translational modifications, including phosphorylation, glycosylation and ubiquitylation, leading to diverse physiological consequences and modulation of its biological activity. There is increasing evidence that methylation may parallel other post-translational modifications in the regulation of various biological processes. It is still not known, however, whether EGFR is regulated by this post-translational event. Here, we show that EGFR Arg 1175 is methylated by an arginine methyltransferase, PRMT5. Arg 1175 methylation positively modulates EGF-induced EGFR trans-autophosphorylation at Tyr 1173, which governs ERK activation. Abolishment of Arg 1175 methylation enhances EGF-stimulated ERK activation by reducing SHP1 recruitment to EGFR, resulting in augmented cell proliferation, migration and invasion of EGFR-expressing cells. Therefore, we propose a model in which the regulatory crosstalk between PRMT5-mediated Arg 1175 methylation and EGF-induced Tyr 1173 phosphorylation attenuates EGFR-mediated ERK activation.
Nature Cell Biology 02/2011; 13(2):174-81. · 19.49 Impact Factor
-
Yongkun Wei,
Ya-Huey Chen,
Long-Yuan Li,
Jingyu Lang,
Su-Peng Yeh,
Bin Shi,
Cheng-Chieh Yang,
Jer-Yen Yang, Chun-Yi Lin,
Chien-Chen Lai,
Mien-Chie Hung
[show abstract]
[hide abstract]
ABSTRACT: Enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of Polycomb repressive complex 2 (PRC2) and catalyses the trimethylation of histone H3 on Lys 27 (H3K27), which represses gene transcription. EZH2 enhances cancer-cell invasiveness and regulates stem cell differentiation. Here, we demonstrate that EZH2 can be phosphorylated at Thr 487 through activation of cyclin-dependent kinase 1 (CDK1). The phosphorylation of EZH2 at Thr 487 disrupted EZH2 binding with the other PRC2 components SUZ12 and EED, and thereby inhibited EZH2 methyltransferase activity, resulting in inhibition of cancer-cell invasion. In human mesenchymal stem cells, activation of CDK1 promoted mesenchymal stem cell differentiation into osteoblasts through phosphorylation of EZH2 at Thr 487. These findings define a signalling link between CDK1 and EZH2 that may have an important role in diverse biological processes, including cancer-cell invasion and osteogenic differentiation of mesenchymal stem cells.
Nature Cell Biology 01/2011; 13(1):87-94. · 19.49 Impact Factor
-
Chao-Kai Chou,
Dung-Fang Lee,
Hui-Lung Sun,
Long-Yuan Li, Chun-Yi Lin,
Wei-Chien Huang,
Jung-Mao Hsu,
Hsu-Ping Kuo,
Hirohito Yamaguchi,
Ying-Nai Wang,
Mo Liu,
Hsin-Yi Wu,
Pao-Chi Liao,
Chia-Jui Yen,
Mien-Chie Hung
[show abstract]
[hide abstract]
ABSTRACT: MAX dimerization protein 1 (MAD1) is a transcription suppressor that antagonizes MYC-mediated transcription activation, and the inhibition mechanism occurs mainly through the competition of target genes' promoter MYC binding sites by MAD1. The promoter binding proteins switch between MYC and MAD1 affects cell proliferation and differentiation. However, little is known about MAD1's regulation process in cancer cells. Here, we present evidence that AKT inhibits MAD1-mediated transcription repression by physical interaction with and phosphorylation of MAD1. Phosphorylation reduces the binding affinity between MAD1 and its target genes' promoter and thereby abolishes its transcription suppression function. Mutation of the phosphorylation site from serine to alanine rescues the DNA-binding ability in the presence of activated AKT. In addition, AKT inhibits MAD1-mediated target genes (hTERT and ODC) transcription repression and promotes cell cycle and cell growth. However, mutated S145A MAD1 abrogates the inhibition by AKT. Thus, our results suggest that phosphorylation of MAD1 by AKT inhibits MAD1-mediated transcription suppression and subsequently activates the transcription of MAD1 target genes.
Molecular Carcinogenesis 07/2009; 48(11):1048-58. · 3.16 Impact Factor
-
Qingqing Ding,
Longfei Huo,
Jer-Yen Yang,
Weiya Xia,
Yongkun Wei,
Yong Liao,
Chun-Ju Chang,
Yan Yang,
Chien-Chen Lai,
Dung-Fang Lee,
Chia-Jui Yen,
Yun-Ju Rita Chen,
Jung-Mao Hsu,
Hsu-Ping Kuo, Chun-Yi Lin,
Fuu-Jen Tsai,
Long-Yuan Li,
Chang-Hai Tsai,
Mien-Chie Hung
[show abstract]
[hide abstract]
ABSTRACT: Myeloid cell leukemia-1 (Mcl-1), a Bcl-2-like antiapoptotic protein, plays a role in cell immortalization and chemoresistance in a number of human malignancies. A peptidyl-prolyl cis/trans isomerase, Pin1 is involved in many cellular events, such as cell cycle progression, cell proliferation, and differentiation through isomerizing prophosphorylated substrates. It has been reported that down-regulation of Pin1 induces apoptosis, and that Erk phosphorylates and up-regulates Mcl-1; however, the underlying mechanisms for the two phenomena are not clear yet. Here, we showed that Pin 1 stabilizes Mcl-1, which is required for Mcl-1 posphorylation by Erk. First, we found expression of Mcl-1 and Pin1 were positively correlated and associated with poor survival in human breast cancer. We then showed that Erk could phosphorylate Mcl-1 at two consensus residues, Thr 92 and 163, which is required for the association of Mcl-1 and Pin1, resulting in stabilization of Mcl-1. Moreover, Pin1 is also required for the up-regulation of Mcl-1 by Erk activation. Based on this newly identified mechanism of Mcl-1 stabilization, two strategies were used to overcome Mcl-1-mediated chemoresistance: inhibiting Erk by Sorafenib, an approved clinical anticancer drug, or knocking down Pin1 by using a SiRNA technique. In conclusion, the current report not only unravels a novel mechanism to link Erk/Pin1 pathway and Mcl-1-mediated chemoresistance but also provides a plausible combination therapy, Taxol (Paclitaxel) plus Sorafenib, which was shown to be effective in killing breast cancer cells.
Cancer Research 09/2008; 68(15):6109-17. · 7.86 Impact Factor
